News

Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting
The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene ...
Sarepta Says Another Patient Died After Receiving Gene Therapy
Sarepta Therapeutics Inc. said another patient has died from acute liver failure after receiving one of its gene therapies, putting additional pressure on the biotech company after the recent deaths ...
Sarepta to cut 500 jobs, add black-box warning on gene therapy
Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients ...
Sarepta to cut 500 jobs after gene therapy setback, shares jump
Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after the recent deaths of two patients who had received its gene therapy Elevidys. Its shares ...
Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures
The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.
Biotech pauses trial after second patient death linked to gene therapy
Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular dystrophy.
Sarepta Therapeutics to Restructure, Lay Off 500 Workers
The restructuring involves laying off about 500 employees, which is estimated to save $120 million in annual costs in 2026. This year, Sarepta expects to save about $100 million, net of estimated ...